CD274 and non-small cell lung carcinoma: In several retrospective meta-analyses studies examining combination treatments in NSCLC patients, PD-1/PD-L1 inhibitor plus chemotherapy was associated with significantly improved PFS, ORR, and OS in first-line therapy, compared with chemotherapy monotherapy, at the expense of increased treatment-related adverse events [156,157].